VTE Risk in Cancer
In this Section
Cancer-associated thrombosis (CAT) is a common cause of death amongst the cancer population.
The increased risk of recurrent venous thromboembolism (VTE) and bleeding complications in patients with cancer makes anticoagulant treatment and management of VTE challenging1.
The pathophysiology of VTE includes general and biological risk factors, common to cancer and non-cancer patients, however in patients with malignancy there are an additional number of disease-specific factors, which render the pathogenesis unique11.
The thrombotic generation process in the cancer patient is distinct from the non-cancer population.
The incidence of VTE increases exponentially with the increase in presented risk factors.
A thorough risk score system and risk stratification is essential to help physicians plan particular prophylactic approaches for patients prone to develop the disease12.
References
- Agnelli, G. et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N. Engl. J. Med. 2020;382:1599–1607
- Kushner, A., West, DO, W. P. & Pillarisetty, L. S. Virchow Triad. StatPearls (StatPearls Publishing, 2019).
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.